Exclusive: Formation Bio licenses IMIDomics IBD drugnews2025-07-29T10:00:12+00:00July 29th, 2025|Endpoints News|
Apellis and Sobi’s Empaveli clinches FDA approval for rare kidney diseasesnews2025-07-29T08:25:34+00:00July 29th, 2025|Endpoints News|
Bristol Myers sends five immunology assets to new $300M biotechnews2025-07-29T02:16:36+00:00July 29th, 2025|Endpoints News|
Sarepta to resume shipping Duchenne therapy after FDA reversalnews2025-07-28T21:03:04+00:00July 28th, 2025|Endpoints News|
Kennedy pledges to ‘fix’ the vaccine injury compensation programnews2025-07-28T18:59:57+00:00July 28th, 2025|Endpoints News|
Pharmaceutical tariffs included in new US-EU trade deal, White House saysnews2025-07-28T17:20:55+00:00July 28th, 2025|Endpoints News|
Sarepta pays out $100M milestone to Arrowhead; Boehringer signs up to $1B dealnews2025-07-28T15:28:02+00:00July 28th, 2025|Endpoints News|
Adaptimmune to sell cell therapy assets, including Tecelra, and lay off more staffnews2025-07-28T15:27:42+00:00July 28th, 2025|Endpoints News|
Roche doubles down on its Alzheimer’s ambitions as next-gen amyloid-lowering drug excites scientistsnews2025-07-28T15:18:41+00:00July 28th, 2025|Endpoints News|
MapLight gets $372.5M for CNS pipeline in year’s third-largest private roundnews2025-07-28T13:35:24+00:00July 28th, 2025|Endpoints News|
